Skip to content

Released Nov 1, 2017, after the close

10-Q filed Nov 1, 2017, 32 days after period end · 0001564590-17-020777

Q3 2017 · 10-Q
Revenue$1.03M±0.0% vs Q3 2016±0.0% vs Q2 2017
Net Income-$10.68MN/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.26N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$10,340,000N/M
Operating Cash Flowderived-$9,769,000N/M
Free Cash Flowderived-$10,131,000N/M
Margins · derived
Operating margin-1007.8%−190.2 pt vs Q3 2016
Net margin-1041.3%−189.8 pt vs Q3 2016

What the release said

The release

Same quarter

MetricQ3 2017Q3 2016Q3 2015Q3 2014
Revenue$1.03M$1.03M$1.03M—
Net Income-$10.68M-$8.74M-$6.89M-$6.60M
EPS Diluted-$0.26-$0.27-$0.24-$0.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR